Abstract:Abstract Background PD-1 is an immune checkpoint on T cells, and interventions to block this receptor result in T cell activation and enhanced immune response to tumors and pathogens. Reciprocally, despite a decade of research, approaches to treat autoimmunity with PD-1 agonists have only had limited successful. To resolve this, new methods must be developed to augment PD-1 function beyond engaging the receptor. Methods We conducted a flow cytometry analysis of T cells isolated from the peripheral blood and synovial fluid of patients with rheumatoid arthritis. In addition, we performed a genome-wide CRISPR/Cas9 screen to identify genes associated with PD-1 signaling. We further analyzed genes involved in PD-1 signaling using publicly available bulk and single-cell RNA sequencing datasets. Results Our screen confirmed known regulators in proximal PD-1 signaling and, importantly, identified an additional 1112 unique genes related to PD-1 ability to inhibit T cell functions. These genes were strongly associated with the response of cancer patients to PD-1 blockades and with high tumor immune dysfunction and exclusion scores, confirming their role downstream of PD-1. Functional annotation revealed that the most significant genes uncovered were those associated with known immune regulation processes. Remarkably, these genes were considerably downregulated in T cells isolated from patients with inflammatory arthritis, supporting their overall inhibitory functions. A study of rheumatoid arthritis single-cell RNA sequencing data demonstrated that five genes, KLRG1, CRTAM, SLAMF7, PTPN2, and KLRD1, were downregulated in activated and effector T cells isolated from synovial fluids. Backgating these genes to canonical cytotoxic T cell signatures revealed PD-1 + HLA-DR HIGH KLRG1 LOW T cells as a novel inflammatory subset of T cells. Conclusions We concluded that PD-1 + HLA-DR HIGH KLRG1 LOW T cells are a potential target for future PD-1 agonists to treat inflammatory diseases. Our study uncovers new genes associated with PD-1 downstream functions and, therefore, provides a comprehensive resource for additional studies that are much needed to characterize the role of PD-1 in the synovial subset of T cells.

The PD-1/PD-L pathway in rheumatic diseases

Programmed Death 1 Ligand (Pd-L) 1 And Pd-L2 Limit Autoimmune Kidney Disease: Distinct Roles

PD-1 immunobiology in systemic lupus erythematosus

The role of PD-1 signaling in health and immune-related diseases

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer

PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis

PD-1 regulation in immune homeostasis and immunotherapy

Mechanism of PD-1/PD-L1 in Regulating cTfr/cTfh Balance in Patients with Rheumatoid Arthritis

PD-1/PD-L1 in cardiovascular disease

The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus

Characteristics of PD‐1+CD4+ T cells in peripheral blood and synovium of rheumatoid arthritis patients

PD-1 and PD-1 ligands: from discovery to clinical application

Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis

P2X7 receptor: A potential therapeutic target for autoimmune diseases

Role of PD-1/PD-L in regulating immune responses

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases

PD-1/PD-L1 pathway: A double-edged sword in periodontitis

The immunomodulatory role of PDEs inhibitors in immune cells: therapeutic implication in rheumatoid arthritis

PDIA3 orchestrates effector T cell program by serving as a chaperone to facilitate the non-canonical nuclear import of STAT1 and PKM2

Exploring the role of programmed cell death protein 1 and its ligand 1 in eye diseases

The Role of PD-L1 on Langerhans Cells in the Regulation of Psoriasis